Intravenous immunoglobulin treatment for patients with primary or secondary progressive Multiple Sclerosis

Background: Intravenous immunoglobulin (IVIG) has a number of potential effects that may be beneficial in multiple sclerosis (MS): neutralisation of autoantibodies against myelin proteins, down-regulation of T or B cells or pro-inflammatory cytokines, functional blockade of Fc receptors on macrophages and inhibition of complement activation. Objective: To evaluate the reduction of progression, functional improvement and safety of low dose immunoglobulin (400mg/kg bodyweight) in patients with secondary and primary progressive MS. Methods: In this randomised, double-blind, placebo controlled multicenter study 231…